Examining the Feasibility of an Application-Based Patient-Reported Outcome Monitoring for Breast Cancer Patients: A Pretest for the PRO B Study

Anna Maria Hage, Pimrapat Gebert, Friedrich Kühn, Therese Pross, Ulrike Grittner and Maria Margarete Karsten
Additional contact information
Anna Maria Hage: Department of Gynecology and Breast Center, Charité—Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
Pimrapat Gebert: Berlin Institute of Health at Charité—Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
Friedrich Kühn: Department of Gynecology and Breast Center, Charité—Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
Therese Pross: Department of Gynecology and Breast Center, Charité—Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
Ulrike Grittner: Berlin Institute of Health at Charité—Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
Maria Margarete Karsten: Department of Gynecology and Breast Center, Charité—Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany

IJERPH, 2022, vol. 19, issue 14, 1-8

Abstract: In preparation for the PRO B study which aims to examine the effects of an app-based intensified patient-reported outcome (PRO) monitoring for metastatic breast cancer patients, prior assessment of its feasibility was carried out. Sixteen breast cancer patients visiting the breast cancer unit at Charité were recruited and downloaded an app connected to an ePRO system. They received electronic questionnaires on two occasions (baseline and the following week) and were subsequently contacted for a semi-structured phone interview for evaluation. Eleven participants answered at least one questionnaire. Some participants did not receive any or only a part of the questionnaires due to technical problems with the app. Participants who completed the evaluation questionnaire ( n = 6) were overall satisfied with the weekly PRO questionnaire. All interviewed ( n = 11) participants thought it was feasible to answer the PRO questionnaires on a weekly basis for one year, as planned in the PRO B study. The pretest revealed a need for major technical adjustments to the app because push notifications about the receipt of new questionnaires were not displayed on some smartphone models. Due to the low number of participants, generalization of the findings is limited to our specific context and study. Nevertheless, we could conclude that if technical aspects of the app were improved, the PRO B study could be implemented as planned. The ePRO questionnaire was considered feasible and adequate from the patients’ perspectives.

Keywords: patient reported outcomes; metastatic breast cancer; health apps; personalized medicine; ePROs; mobile health application; mHealth (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/14/8284/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/14/8284/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:14:p:8284-:d:857370

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().